|
CONCOMITANT USE WITH POTASSIUM SUPPLEMENTS OR SALT SUBSTITUTE CONTAINING POTASSIUM MAY LEAD TO HYPERKALEMIA.
|
CONCOMITANT USE WITH POTASSIUM SUPPLEMENTS OR SALT SUBSTITUTE CONTAINING POTASSIUM MAY LEAD TO HYPERKALEMIA.
|
CONCOMITANT USE WITH POTASSIUM SUPPLEMENTS OR SALT SUBSTITUTE CONTAINING POTASSIUM MAY LEAD TO HYPERKALEMIA.
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CONCURRENT USE WITH POTASSIUM-SPARING DIURETICS MAY LEAD TO HYPERKALEMIA
|
CONCURRENT USE WITH POTASSIUM-SPARING DIURETICS MAY LEAD TO HYPERKALEMIA
|
CONCURRENT USE WITH POTASSIUM-SPARING DIURETICS MAY LEAD TO HYPERKALEMIA
|
CO-ADMINISTRATION LEADS TO AN INCREASE OF ABOUT 18% IN AUC OF LOSARTAN WITH NO EFFECT ON PHARMACOKINETICS OF ITS ACTIVE METABOLITES
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY RESULT IN INCREASED HYPOTENSIVE EFFECT
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
OESTROGENS REDUCE EFFECTS OF ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
ANTIHYPERTENSIVE EFFECT OF LOSARTAN MAY BE BLUNTED BY INDOMETHACIN
|
ANTIHYPERTENSIVE EFFECT OF LOSARTAN MAY BE BLUNTED BY INDOMETHACIN
|
CO-ADMINISTRATION LEADS TO A REDUCTION OF ABOUT 20% IN AUC OF LOSARTAN AND THAT OF ITS ACTIVE METABOLITES
|
CO-ADMINISTRATION LEADS TO A REDUCTION OF ABOUT 20% IN AUC OF LOSARTAN AND THAT OF ITS ACTIVE METABOLITES
|
CO-ADMINISTRATION LEADS TO A REDUCTION OF ABOUT 20% IN AUC OF LOSARTAN AND THAT OF ITS ACTIVE METABOLITES
|
CO-ADMINISTRATION LEADS TO A REDUCTION OF ABOUT 20% IN AUC OF LOSARTAN AND THAT OF ITS ACTIVE METABOLITES
|
CO-ADMINISTRATION LEADS TO A REDUCTION OF ABOUT 20% IN AUC OF LOSARTAN AND THAT OF ITS ACTIVE METABOLITES
|
CO-ADMINISTRATION LEADS TO A REDUCTION OF ABOUT 20% IN AUC OF LOSARTAN AND THAT OF ITS ACTIVE METABOLITES
|
ALISKIREN PLASMA CONCENTRATION IS REDUCED UP TO 50%
|